Rituximab/Paclitaxel

利妥昔单抗/紫杉醇

Report date: 2025/07/17 10:59:50

Base Information

Drug NameRituximab/Paclitaxel
Drug Alias Name紫杉醇/利妥昔单抗Nab-paclitaxel/RituximabRituximab/Nab-paclitaxelPaclitaxel/RituximabRituximab/Abraxane +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTubulin inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effects +[6] 
TargetsB-lymphocyte antigen CD20TubulinProgrammed cell death protein 1
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes PaclitaxelRituximab
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesMayo Clinic
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A